OR WAIT null SECS
December 18, 2018
Agilent and other partners are funding development of Tapestri, a single-cell sequencing platform designed to help predict cancer relapse in individual patients and show the efficacy of gene-editing experiments.
The companies will develop a digital platform for the development and lifecycle management of antibiotics.
December 14, 2018
Roquette has announced the completion of its acquisition of a majority stake in a pharma packaging company based in India.
Eli Lilly and AC Immune have signed a license and collaboration agreement focussing on the R&D of tau aggregation inhibitor small molecules for the potential treatment of neurodegenerative diseases.
Avacta Group and LC Chem Life Sciences have entered into a multi-target collaboration and development agreement.
December 10, 2018
The company will use GE Healthcare’s off-the-shelf KUBio biologics factory, which is expected to start operations in 2020, to provide development and manufacturing for early- to late-clinical and early-commercial manufacturing stages.
FDA has approved Truxima (rituximab-abbs), a biosimilar to Roche’s anti-cancer biologic, Rituxan (rituximab).
The companies aim to advance research into inflammatory bowel disease.
December 05, 2018
The UK's government has revealed the details of the second Life Sciences sector deal, forming part of the Industrial Strategy.
November 30, 2018
The acquisition will give Genentech full rights to Jecure’s preclinical portfolio of NLRP3 inhibitors.